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One Sentence Summary: Using a new method of identifying and tracking donor-reactive T 
cells in transplant recipients, we have obtained evidence for clonal deletion as a mechanism of 
graft tolerance following combined kidney and bone marrow transplantation in humans. 
 
Abstract: T cell responses to allogeneic major histocompatibility (MHC) antigens present a 
formidable barrier to organ transplantation, necessitating long-term immunosuppression to 
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minimize rejection. Chronic rejection and drug-induced morbidities are major limitations that 
could be overcome by allograft tolerance induction. Tolerance was first intentionally induced in 
humans via combined kidney and bone marrow transplantation (CKBMT), but the mechanisms 
of tolerance in these patients are incompletely understood. We now establish an assay to identify 
donor-reactive T cells and test the role of deletion in tolerance after CKBMT. Using high-
throughput sequencing of the TCRB chain CDR3 region, we define a fingerprint of the donor-
reactive T cell repertoire prior to transplantation and track those clones post-transplant. We 
observed post-transplant reductions in donor-reactive T cell clones in three tolerant CKBMT 
patients; such reductions were not observed in a fourth, non-tolerant, CKBMT patient or in two 
conventional kidney transplant recipients on standard immunosuppressive regimens. T cell 
repertoire turnover due to lymphocyte-depleting conditioning only partially accounted for the 
observed reductions in tolerant patients; in fact, conventional transplant recipients showed 
expansion of circulating donor-reactive clones, despite extensive repertoire turnover.  Moreover, 
loss of donor-reactive T cell clones more closely associated with tolerance induction than in vitro 
functional assays. Our analysis supports clonal deletion as a mechanism of allograft tolerance in 
CKBMT patients. The results validate the significance of donor-reactive T cell clones identified 
pre-transplant by our method, supporting further exploration as a potential biomarker of 
transplant outcomes. 
 
[Main Text:] 
Introduction 
Chronic immunosuppression in kidney transplantation is associated with morbidities 
including nephrotoxicity, metabolic abnormalities, and increased risk of infection and 
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malignancy (1). Moreover, despite recent improvements in one-year kidney allograft survival, 
late rejection rates remain high (2). Immune tolerance in organ transplantation, defined as the 
absence of rejection without immunosuppression, would avoid these morbidities. Spontaneous 
tolerance is rare in conventional renal transplant recipients, with frequencies estimated at less 
than five percent (3, 4).  
Tolerance was first intentionally induced in humans via combined kidney and non-
myeloablative bone marrow transplantation (CKBMT), a protocol designed to induce a mixed 
chimeric state in which hematopoietic elements are comprised of a mixture of host and donor 
cells (5, 6). Among ten patients who received CKBMT (five subjects in Immune Tolerance 
Network [ITN] study NKDO3; five subjects in the study ITN 036ST), seven have tolerated their 
allograft off immunosuppression for 4-12 years (6-8). 
 In the rodent regimens that led to the development of this protocol, mixed chimerism 
was durable and tolerance involved long-term intrathymic deletion of donor-reactive T cells (ie 
“central tolerance”) (9-11). In human CKBMT patients, however, mixed chimerism was transient 
(6, 12), suggesting that additional, likely peripheral, mechanisms are involved in maintaining 
long-term tolerance. Functional mechanistic studies in these CKBMT patients suggested a role 
for early suppression and long-term deletion of donor-reactive T cells in maintaining tolerance 
(6, 13). In vitro assays, however, cannot reliably distinguish anergy from deletion as mechanisms 
of unresponsiveness. We now establish an assay to specifically track donor-reactive T cells and 
test the role of deletion in maintaining long-term tolerance after CKBMT. 
 Tracking of donor-reactive clones in transplant patients is hampered by the large 
proportion (up to 10%) of T cells directly recognizing a set of MHC alloantigens (14, 15), 
presumably involving many specificities. We devised a deep sequencing approach to identify 
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and track the donor-reactive T cell repertoire. Using ImmunoSEQ (Adaptive™), TCR β (TRB) 
CDR3 regions are amplified with primers for all 54 known expressed Vβ and all 13 Jβ regions 
adapted for solid phase PCR and high throughput sequencing (16-18). Each individual T cell 
clone has a distinct TRB CDR3 sequence. We hypothesized that CDR3 sequencing of a 
transplant recipient’s donor-reactive T cells, as identified by their proliferation in an anti-donor 
mixed lymphocyte reaction (MLR) prior to transplant, would identify donor-specific TCR 
sequences that could then be physically tracked in the recipient’s post-transplant peripheral blood 
samples to differentiate between anergy and deletion of donor-specific T cells. Using this 
analysis in four CKBMT and two conventional renal allograft recipients, we obtained evidence 
for clonal deletion as a mechanism of allograft tolerance in humans. 
Results  
Defining a “fingerprint” of the anti-donor T cell repertoire 
Figure 1 illustrates our strategy for defining the “fingerprint” of the alloreactive repertoire 
for any responder-stimulator (recipient-donor) pair. An allostimulated population was generated 
via CFSE MLR: MLR responders and irradiated stimulator PBMCs were labeled with CFSE and 
violet dye respectively, co-cultured for 6 days, then FACS sorted for violet negative, CD3-
positive, CFSE-low CD4+ and, in separate tubes, CD8+ cells (Fig. 1A).Deep sequencing was 
then performed on the genomic DNA extracted from these sorted T cell populations that had 
divided in response to donor antigens. To permit identification of clones expanding in the MLR, 
deep sequencing was also performed on unstimulated CD3+CD4+ and CD3+CD8+ FACS-sorted 
T cells from the same pre-transplant peripheral blood sample. To be considered donor-reactive, a 
clone defined by the unique nucleotide sequence of its TRB CDR3 region must have been 
detected above a minimum frequency threshold of 10
-4
 in the CFSE-low population in the 
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stimulated (MLR) sample and have expanded at least 5-fold relative to its frequency in an 
unstimulated sample from the same time point, thereby excluding highly-abundant but not 
specifically donor-reactive clones (Fig.1B). We could thus define a “fingerprint” of the pre-
transplant donor-reactive T cell repertoire for each donor-recipient pair and these clones could be 
tracked in unstimulated post-transplant samples. 
 
Reproducible detection of alloreactive TCR in blood samples obtained at different times   
To validate the approach of tracking a set of alloreactive TRBs over time, we tested 
whether individual alloreactive T cell clones could be reproducibly detected in blood samples 
drawn at multiple times. Using PBMCs obtained from three healthy controls at different time 
points separated by two-week or one-year intervals, we set up parallel MLRs with the same 
responder-stimulator pairs for each time point. We then performed deep sequencing on the 
dividing T cells in the MLR as well as on unstimulated T cells (Fig. S1B,C). Deep CDR3 
sequencing identified fewer unique clones in allostimulated versus unstimulated populations, 
resulting in decreased entropy and increased clonality, a trend that was most striking in the CD4 
compartment (Table S1).  
A comparison of the log clonal frequencies from the MLRs (stimulated samples) 
separated by two weeks showed strong linear correlations among CD4 (r = 0.7) and CD8 (r = 
0.8) clones, but minimal correlation with the unstimulated repertoire (CD4: r = 0.3; CD8: r = 
0.2); the linear correlation persisted in the clonal frequencies identified in MLRs from blood 
draws separated by a year-long interval (Fig. 2A). Figure 2B shows the relative frequency 
overlap of the alloreactive clones (defined in Figure 1) between the two time points for each 
healthy control. The degree of overlap was comparable between the three samples, including 
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across the two week (HC#1) and year-long (HC#2, HC#3) time intervals. There was less overlap 
in alloreactive CD8 than CD4 T cell clones detected at different time points. This may reflect the 
presence of a few very high frequency clones in the unstimulated CD8 repertoires (Fig. 2A), 
resulting in fewer unique CD8 clones being sampled in each blood draw (Table S1). Indeed, the 
diversity of the unstimulated CD8 repertoires was less than that of CD4s:  the clonality of a pool 
of identical clones is “1” while that of a pool of all unique clones is “0;” the significantly 
increased clonality of CD8 compared to CD4 cells in the same unstimulated samples is shown in 
Fig. 2C (p = 0.0062, n = 5, two-tailed paired t test). Cumulatively, all alloreactive CD4 clones 
comprised approximately 48-80% of clones in each MLR and less than 1.1% of the unstimulated 
CD4 repertoire (Table S2). For the CD8s, the alloreactive clones accounted for 64-80% of the 
stimulated population and less than 2.5% of the unstimulated population (Fig. 2D). Taken 
together, our healthy control studies showed that the alloreactive T cell populations identified via 
CFSE MLR that recognized a given set of alloantigens were reproducibly detectable in separate 
peripheral blood samples over highly disparate time intervals ranging from 2 weeks to 1 year.  
 
Reduced circulating donor-reactive T cell clones in tolerant CKBMT patients 
 Our studies of alloreactive T cells in healthy controls showed that donor-reactive clones 
identified in MLRs could be consistently detected in peripheral blood at disparate time points. 
We therefore used this approach to identify donor-reactive T cells pre-transplant and track them 
over time post-transplant in six subjects: four CKBMT recipients (Subjects 1, 2, 4, and 5 from 
ITN trial ITN036ST) who were removed from immunosuppression eight months post-transplant 
and two kidney transplant recipients receiving conventional immunosuppression (IS#1 and 
IS#2). Sequencing statistics are summarized in Table S3. For each transplant recipient, we 
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defined a “fingerprint” of the anti-donor T cell repertoire using pre-transplant PBMCs. The limit 
of detection of T cell clones for tracking in the unstimulated pre- and post-transplant samples 
was determined with a power calculation that took into account the number of reads obtained 
from each sample. 
CKBMT Subject 1 has stable allograft function >5 years after stopping 
immunosuppression at 8 months post-transplant (Fig. 3A). All CD4 and CD8 samples permitted 
clonal detection at ≥10-5 frequency. We identified 2200 donor-reactive CD4+ clones and 1192 
CD8
+
 clones as defined by our approach in Figure 1B.  We then compared the number of these 
donor-reactive that were detectable in unstimulated pre- and post-transplant blood samples. A 
significant reduction in the number of circulating donor-reactive CD4+ and CD8+ clones was 
observed at both 6 and 18 months post-transplant compared to pre-transplant blood (Figs. 3B, 
S3, S4; Table S4). Results were robust to changes in definition of donor-reactive clones ranging 
from 5-fold to 10-fold for all subjects; the 5-fold expansion criterion included the largest number 
of clones while excluding clones with minimal expansion that might reflect “bystander” effects 
(Fig. S2).  
Functional MLR assays in Subject 1 (Fig. 3C) showed persistent anti-donor reactivity 
(greater than anti-self) at 6 months that was markedly reduced at 1.5 years (comparable to anti-
self), while cell-mediated lympholysis (CML) assays (Fig. 3D) revealed donor unresponsiveness 
at both times; responses to extensively HLA-mismatched (from donor and recipient) third party 
donors recovered between 6 and 18 months post-transplant, demonstrating that immune 
unresponsiveness was specific to the donor. Limiting dilution analyses (LDA) quantify 
functional cytotoxic T lymphocyte precursors (CTLp) and IL-2-producing helper T lymphocytes 
(HTL) (Fig. S5). Donor-reactive CTLp were undetectable by 6 months, suggesting the remaining 
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donor-reactive cells were anergic, as only partial deletion of donor-reactive CD8 cells was 
apparent (Fig. 3B). Anti-donor HTL were measureable at 6 but not 18 months.   
 We performed similar analyses in two additional tolerant CKBMT recipients. Subject 2 is 
>5 years post-CKBMT with no rejection. Her pre-transplant MLR was weak, perhaps due to 
extensive HLA sharing with the donor (Table S3 legend). Significantly fewer CD4+ and CD8+ 
donor-reactive clones were detected at 6, 12, and 24 months after CKBMT than before (Figs. 3B, 
S3, S4; Table S4). While TCR analysis revealed residual donor-reactive CD4 clones, functional 
assays (Figs. 3C,D, S5) showed minimal to no post-transplant responses to donor, with recovery 
of third party responses at 18 months in MLR and CML (8).   
 Subject 4 also shows allograft tolerance >4.5 years after CKBMT. Figure 3B shows a 
progressive reduction in CD8+ donor-reactive clones reaching significance at 12 months post-
transplant; donor-reactive CD4+ clones showed an initial non-significant increase at 6 months 
post-transplant followed by significant reductions at 12 and 24 months (Figs. 3B, S3, S4; Table 
S4). Several functional assays, including the MLR, revealed persistent anti-donor responsiveness 
at 12 and 18 months (Figs. 3C,D, S5), unlike Subjects 1 and 2 and NKDO3 subjects (13). To test 
whether the same clones responded to the donor in post- and pre-transplant MLRs, we performed 
clonal analysis on one-year CD4+ and CD8+ T cells dividing in anti-donor CFSE MLR. The 
overlap of alloreactive clones over one year was markedly less than that observed in healthy 
controls over the same interval (Fig. S6A and Fig. 2B, respectively). The number of post-
transplant donor-reactive CD4 and CD8 T cells defined by the 12-month MLR (clones with 
frequencies ≥10-4 in the 12 month post-transplant MLR expanded at least 5-fold compared to the 
unstimulated 12 month post-transplant sample) remained relatively constant in unstimulated pre- 
and post-transplant blood samples (Fig. S6B). Collectively, these data suggest that the persistent 
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MLR in Subject 4 was largely mediated by a subset of clones that did not lead to rejection, some 
of which may have developed post-transplant, others of which did not expand sufficiently in the 
pre-transplant MLR to be defined as alloreactive, escaped deletion by condition treatment, and 
were neither expanded nor deleted in the presence of the donor graft.   
 
No reduction in donor-reactive clones in a CKBMT recipient who failed tolerance induction 
 One month after discontinuing immunosuppression, CKBMT Subject 5 developed acute 
rejection that culminated in graft loss despite anti-rejection therapy (Fig. 3A). Of the four 
CKBMT recipients, only Subject 5 showed no significant reduction in numbers of circulating 
donor-reactive CD4 and CD8 clones after transplantation (Figs. 3B, S3,S4; Table S4). 
Remarkably, MLR, CML and CTLp assays showed donor-specific unresponsiveness at 6 and 12 
months (Figs. 3C,D, S5). Thus, the functional assays did not distinguish the lack of clinical 
tolerance, whereas the clonal analysis showed a distinct pattern compared to the three tolerant 
subjects.  
 
Lack of deletion of donor-reactive clones in conventional kidney transplant recipients  
 To provide a further comparison to tolerant CKBMT recipients, we studied two kidney 
transplant recipients receiving conventional immunosuppression. Subject IS#1 received a living 
unrelated donor kidney. Subject IS#2 received a living unrelated donor kidney after a failed prior 
living-related transplant, and had Banff grade 1B acute cellular rejection at 3 months post-
transplant. In contrast to tolerant patients, donor-reactive CD4+ clones were significantly 
enriched in the post-transplant compared to pre-transplant peripheral blood in IS#1 and IS#2. 
Donor-reactive CD8+ clones were not significantly changed (Figs. 4A, S7; Table S4). 
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Figure 4B summarizes the fold change in the number of donor-reactive clones detected in 
post-transplant as compared to pre-transplant blood in all six transplant patients. In contrast to 
the three tolerant CKBMT subjects, there was no significant reduction in either of the two 
“conventional” kidney transplant subjects or the non-tolerant CKBMT subject in circulating 
donor-reactive CD4 and CD8 T cell clones. Of note, the limited number of donor-reactive CD8 
clones tracked in Subject 5 and IS#2 limited the ability to evaluate changes over time. For non-
tolerant subjects, observed expansion of donor-reactive CD4 cells was greater when the 
definition of donor reactivity required greater expansion in the pre-transplant MLR (Fig. S2), 
suggesting that the donor-reactive pre-transplant clones responding most strongly in MLR were 
most likely to expand post-transplant.   
As additional controls, an identical analysis was performed in healthy controls in whom 
clones defined as alloreactive in a particular MLR were tracked in an unstimulated sample one 
year later. For both CD4 and CD8 T cells, there was no significant change in the number of 
alloreactive T cells, in contrast to the reduction seen in the tolerant CKBMT subjects and the 
expansion in donor-reactive CD4 cells in the “conventional” transplant patients (Fig. 4B, details 
Table S5).  
 
T cell repertoire turnover  
 The loss of donor-specific clones in tolerant subjects might reflect global T cell depletion 
due to conditioning, leading to repertoire turnover as T cells developed de novo from thymic 
recovery. To quantify changes in T cell repertoire over time, we calculated the Jensen-Shannon 
Divergence (JSD) of the top 1000 nucleotide sequences pre- and post-transplant (Fig. 5A). A 
JSD of “1” reflects complete divergence of two repertoires, while the JSD of two identical 
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repertoires is “0”. For reference, we determined JSD of pairs of samples of T cells isolated from 
peripheral blood one year apart from two healthy controls. While all transplant recipients showed 
greater repertoire divergence than healthy controls, JSD values were higher for CD4+ 
populations of CKBMT recipients as compared to CD8+ T cells. Among the “conventional” 
transplant recipients, IS#2 showed repertoire turnover close to that of the CKBMT patients while 
that of IS#1 was lower. The non-tolerant CKBMT recipient Subject 5 showed the highest JSD, 
with almost complete turnover of CD4 and CD8 repertoires (Fig. 5A). 
We next compared the likelihood, post-transplantation, of detecting any clones detected 
pre-transplant compared to those defined as donor-reactive. Among tolerant subjects, no 
significant decrease in donor-reactive compared to all pre-transplant CD4 clones was observed 
post-transplant. Subject 2 showed a significant relative increase in donor-reactive CD4 cells by 
one year post-transplant and Subject 4 showed a significant relative increase only at 6 months 
post-transplant (Fig. 5B). A significant and sustained reduction in the detection of donor-reactive 
compared to all CD8+ clones was observed in Subjects 2 and 4, suggesting antigen-driven loss 
of donor-reactive CD8 clones (Fig. 5B).  The notion that some, but not all, deletion of donor-
reactive clones in tolerant subjects may have reflected repertoire turnover was supported by 
analysis of third party-reactive T cells identified pre-transplant (Fig. S8), some of which showed 
post-transplant reductions.  
The determination of relative loss of donor-reactive compared to all pre-transplant clones 
was affected by the definition of “donor-reactive” in some subjects.  For example, for Subject 1, 
when this definition required increasing levels of MLR expansion, greater relative loss of donor-
reactive CD4 and CD8 clones was seen (Fig. 5C). This result suggests that more strongly donor-
reactive clones were more likely to show deletion following CKBMT.  Overall, post-transplant 
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reductions in donor-reactive clones in tolerant subjects may reflect a mixture of repertoire 
turnover and specific deletion of donor-reactive T cells, possibly following initial antigen-driven 
expansion.  
 
Reduced TCR diversity in non-tolerant compared to tolerant subjects 
Since lymphopenia-driven proliferation (LIP) in a T cell-deficient environment(19) may 
reduce the repertoire diversity associated with T cell reconstitution after lymphoablative 
conditioning(20), we compared overall clonal diversity (by Simpson’s Index D) of post-
transplant T cell populations (Fig. 6A). In contrast to tolerant subjects, in whom the CD4 T cell 
diversity returned to pre-transplant values, non-tolerant subjects showed persistently decreased 
clonal diversity (increased D) post-transplantation (Student’s t-test p-value 0.017 comparing two 
groups at time point nearest one year post-transplant)(Fig. 6B). No difference was seen between 
the groups in the diversity of CD8 repertoires.  
Discussion  
T cell responses to allogeneic MHC molecules are orders of magnitude stronger than 
other responses (14, 15, 21, 22), presumably involving myriads of T cell receptors. We have 
developed an approach using deep TCR sequencing to identify, prior to transplant, and track, 
following transplantation, human transplant recipients’ donor-reactive T cell repertoires. We 
demonstrate the feasibility of this approach and use it to address mechanisms of tolerance in 
CKBMT recipients.   
Previous studies in ITN CKBMT trial NKDO3 (6, 13) could not distinguish between 
anergy and deletion of donor-reactive T cells in maintaining long-term tolerance. Our new 
method allowed specific assessment of clonal deletion. Circulating donor-reactive CD4+ and 
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CD8+ clones, identified prior to transplantation by CFSE-MLR, decreased after transplantation 
in all tolerant subjects.  Deletion was either partial or not apparent at 6 months and frequently 
evolved over time. In the only CKBMT subject who failed to achieve operational tolerance, 
significant reductions of donor-specific clones were not observed. These studies provide 
evidence for a role for deletion in the maintenance of allograft tolerance in humans. While we 
cannot exclude the possibility that donor-reactive clones moved from the circulation into the 
allograft, this would be inconsistent with protocol biopsies showing no rejection and minimal 
cellular infiltrates, which are enriched for Foxp3+ cells, in tolerant CKBMT recipients(6, 7).   
Conventional transplant recipients showed persistent expansion of donor-reactive T cell 
clones following transplant, despite considerable repertoire turnover, suggesting that expansion 
was allograft-driven and showing that pre-transplant MLRs identify biologically relevant donor-
reactive clones. A role in graft-versus-host-disease was identified for a CD4 clone recognizing a 
recipient minor histocompatibility antigen in MLR following HLA-identical hematopoietic cell 
transplantation (23), but our studies are the first to examine the entire alloreactive repertoire 
against HLA antigens. Further evidence from our studies that biologically significant clones are 
identified in pre-transplant MLR includes the following: 1) The donor-reactive clones expanding 
most strongly in pre-transplant MLR were most likely to be expanded in post-transplant blood in 
non-tolerant subjects (Fig.S2); 2) The donor-reactive clones expanding most strongly in pre-
transplant MLR were more likely than other clones to be deleted in post-transplant blood of 
tolerant subjects (Fig. 5C); 3) Donor-reactive clones that were insufficiently dominant to be 
identified as donor-reactive in pre-transplant MLR persisted in constant numbers and contributed 
to a post-transplant MLR in Subject 4, but did not cause rejection. In contrast, Subject 5 failed to 
show deletion of donor-reactive clones identified in pre-transplant MLR and rejected the graft. 
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These data suggest that non-dominant donor-reactive clones that can produce a post-transplant 
MLR when dominant clones are deleted may be of minimal biological significance, whereas 
those that dominate in the pre-transplant MLR are of major importance.  
Deletion of donor-reactive clones in CKBMT recipients was partially explained by global 
T cell depletion induced by conditioning (6, 7, 12, 13). The initial recovery of T cells in CKBMT 
recipients is most likely driven by LIP, as most T cells express an effector/memory phenotype in 
the first 3-6 months post-transplant (12), as observed for rapid LIP (19), which is largely antigen-
driven (24, 25). Therefore, residual donor-reactive clones may expand initially in response to 
bone marrow and/or kidney alloantigens. However, donor-reactive T cell deletion is unlikely to 
reflect only repertoire turnover, given the similar, high level of repertoire turnover in all CKBMT 
recipients and lack of donor-reactive clonal deletion only in the subject who failed tolerance. The 
persistence of some pre-existing donor-reactive clones along with the sometimes progressive 
deletion observed over time in tolerant patients is consistent with initial LIP/antigen-driven 
expansion of surviving donor-reactive clones. Indeed, two tolerant subjects, while showing an 
absolute loss of donor-reactive CD4 clones, showed an increase in these clones relative to all 
preexisting clones, one at 6 months and another persisting longer post-transplant (Fig. 5B).  
Thus, the relative numbers of persisting donor-reactive and non-donor-reactive clones may be 
the net effect of T cell-depleting conditioning (affecting any clone), antigen-driven expansion 
(donor-reactive clones) and antigen-driven deletion (donor-reactive clones). During rejection, 
entry of donor-reactive T cells, especially CD8 clones, into the graft may also reduce circulating 
clonal frequencies, perhaps mitigating the detection of expanded anti-donor clones in the 
rejecting CKBMT Subject 5. Ultimately, the relative loss of donor-reactive T cell clones was 
greater than that of all clones in several instances in the tolerant subjects. Thus, our data suggest 
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that expanded donor-reactive clones are gradually deleted in tolerant subjects, resulting in 
specific clonal reduction, especially among clones with strongest anti-donor reactivity. 
The reduction of donor-reactive clones in tolerant subjects is consistent with our 
hypothesis that donor-reactive T cells are slowly deleted in response to repeated encounter with 
donor antigens on quiescent, accepted allografts (13). Late deletion seems less likely to occur 
intrathymically, as hematopoietic chimerism was short-lived (12), making long-term intrathymic 
antigen presenting cells (APC) chimerism unlikely. However, peripheral APCs presenting intact 
or processed donor antigen might migrate to the thymus (26) and mediate ongoing deletion.  
Clonal analysis detected persistent donor-reactive clones with greater sensitivity than in 
vitro assays that revealed donor-specific unresponsiveness in CKBMT Subjects 1, 2, and 5. 
Donor-specific unresponsiveness was particularly surprising in the rejector, Subject 5.  Unlike 
the functional assays, TCR clonal analysis is not affected by anergy or suppression. The absence 
of a post-transplant MLR in Subject 5 despite the lack of deletion of dominant donor-reactive 
clones suggests that these clones may have been anergic and that anergy could have been broken 
by the renal infection that preceded rejection (8).  The poor predictive value of MLR and CML 
with respect to graft outcomes is consistent with prior studies in animals (27, 28), patients 
receiving conventional transplants (29-33) and patients receiving a different CKBMT protocol 
for HLA-mismatched kidney allograft tolerance induction (34). Overall, clonal analysis 
distinguished between tolerance and non-tolerance among the six subjects, suggesting a new and 
specific method of assessing transplantation tolerance.  
The similar clonal expansion in two conventional kidney transplant recipients despite 
disparate clinical outcomes (IS#2 but not IS#1 had a rejection) may reflect the limited cell 
numbers available for IS#2, resulting in a higher threshold frequency to declare a clone 
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“present”.  Moreover, important differences in donor-reactive T cell clone numbers might be 
present in the kidney graft and not the circulation and future studies of allograft biopsies and 
urine will be important. Future studies will include analyses of indirect anti-donor alloreactivity, 
which also contributes to rejection (35-37).  
 Repertoire turnover was greater for CKBMT patients compared to the non-rejecting 
conventional transplant recipient, consistent with more potent T cell-depleting treatments in 
conditioning for CKBMT. However, both conventional transplant recipients also showed 
markedly greater TCR turnover than healthy controls over one year, demonstrating the potential 
of our approach to provide insight into the effects of immunosuppressive regimens. In a recent 
report (38) on TCR repertoire  in multiple sclerosis (MS) patients receiving conditioning and 
autologous hematopoietic cell transplantation, T cell diversity recovered more quickly in MS 
patients who responded to treatment compared to non-responders. It is interesting, therefore, that 
CD4 T cell diversity returned to baseline levels more rapidly in tolerant than in non-tolerant 
subjects (Fig. 6A). This return of diversity did not correlate with recovery of naïve-type CD4 
cells, which was more rapid in CKBMT Subjects 4 and 5 than in Subjects 1 and 2 (12).   
Our study is limited by the small number of these tolerant patients available and will 
require further validation in larger cohorts as transient chimerism protocols are evaluated in 
additional subjects. While differences in immunosuppression between the CKBMT and 
conventional patients may have affected the observed clonal behavior, re-establishment of a new 
T cell repertoire due to T cell depleting conditioning is insufficient to account for deletion of 
donor-reactive clones in tolerant patients. Further exploration of how various induction and 
maintenance immunosuppression regimens differentially affect donor-reactive clones after 
transplant will be of interest. 
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 In conclusion, we have described a novel method whereby donor-reactive recipient T cell 
clones are identified pre-transplant, then tracked after transplantation. We obtained evidence for 
a role for deletion of donor-reactive CD4 and CD8 T cells in maintaining tolerance in CKBMT 
recipients with transient chimerism. A recent study (39) used high throughput CDR3 sequencing 
to detect donor-reactive T cells in the graft and urine of a patient with allograft dysfunction. 
However, that study relied on a measurable post-transplant MLR to identify donor-reactive 
clones, and did not assess the fate of pre-existing donor-reactive T cells.  Our approach of 
identifying donor-reactive clones prior to transplantation and tracking them prospectively avoids 
dependence on functional assays post-transplant, which correlate poorly with outcomes. This 
strategy has revealed the biological importance of donor-reactive T cell clones detected in a pre-
transplant MLR, demonstrating post-transplant expansion of these clones even in the face of 
global T cell repertoire turnover and has provided new mechanistic insights into tolerance 
achieved via transient chimerism, implicating eventual peripheral deletion of donor-reactive T 
cells in response to an accepted renal allograft.   
Materials and Methods 
Study Design 
The object of this study was to study the fate of pre-transplant donor-reactive T cells in 
transplant patients and to provide insight into the mechanisms of long-term tolerance in 
CKBMT. Laboratory investigations were performed on four of five CKBMT patients (Subjects 
1, 2, 4, and 5) in study ITN036ST, which included for-protocol PBMC collections pre- and post- 
transplant, and two conventional transplant patients from Columbia’s Center for Translational 
Immunology Biobank Core of transplant recipient clinical specimens. CKBMT Subject 3 was 
removed from ITN036T after early allograft loss due to thrombotic microangiopathy and post-
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transplant PBMCs were therefore not available for analysis. The conventional transplant patients 
studied were those for whom sufficient post-transplant PBMC were available to perform the 
required in vitro assays and for whom one or more post-transplant kidney transplant biopsies, 
clearly indicating rejection or lack thereof, were available. There was no randomization or 
blinding.  
Subjects  
CKBMT subjects: clinical outcomes in five CKBMT patients in study ITN036ST have been 
described (7, 8). Conventional transplant recipients: Subject IS#1 had end-stage renal disease 
(ESRD) secondary to focal segmental glomerulosclerosis (FSGS) and received a renal transplant 
from a living related donor. Subject IS#1 received thymoglobulin and methylprednisolone for 
induction therapy and was subsequently maintained on tacrolimus and mycophenolate. Allograft 
biopsies performed at 10 and 17 months after transplantation to evaluate acute rises in serum 
creatinine showed no evidence of cellular or antibody-mediated rejection, and were consistent 
with calcineurin inhibitor toxicity. Subject IS#2 also had ESRD due to FSGS, and received a 
renal transplant from a living unrelated donor several years after a prior living-related transplant 
had failed. Because the patient was highly sensitized, he received plasmapheresis and IVIg 
preoperatively, and received rituximab, basiliximab, and methylprednisolone as induction 
therapy. A three-month protocol biopsy revealed Banff grade 1B acute cellular rejection (ACR), 
which was treated with thymoglobulin and corticosteroids; subsequent protocol biopsies at 6 
months and 1 year were suspicious for ongoing rejection.Informed consent was obtained from all 
subjects. The study protocols were approved by the Massachusetts General Hospital and 
Columbia University Medical Center Institutional Review Boards.  
Mixed Lymphocyte Reactions  
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Preparation of carboxyfluorescein succinimidyl ester (CFSE)-labeled responders: For HC#1 (T1 
and T2 stim samples) and CKBMT Subjects 1 and 2, MLRs were set up using purified T-cells as 
responders. Previously frozen pre-transplant PBMCs were thawed, washed, and resuspended in 
MACS buffer.  MACS beads (Pan T cell Isolation Kit II, Miltenyi Biotec  catalog # 130-091-
156) were used to generate “untouched” T cells. These T cells were resuspended in PBS at 1x106 
cells/mL, labeled with CFSE at a concentration of 0.2uM-0.5uM (CellTrace CFSE Proliferation 
Kit, Molecular Probes
TM
 (catalog # C34554), washed 3 times, and resuspended in MLR medium 
(AIM-V supplemented with 5% AB heat-inactivated human serum, 0.01M HEPES, and 50 uM 
2-ME at a concentration of 2x10
6
 cells/mL. For HC #2 and #3, CKBMT Subjects 4 and 5, the 
two conventional transplant recipients, and the anti-third party responses, whole PBMC were 
used as responders instead of purified T cells.  PBMCs were labeled with CFSE as above and 
resuspended at 2x10
6 
cells/mL. Preparation of violet dye-labeled stimulators: Cryopreserved 
donor (or healthy control) PBMCs were thawed, washed, resuspended in PBS, and labeled with 
BD Horizon
TM
 Violet Proliferation Dye 450 (catalog # 562158). After labeling, cells were 
washed twice, resuspended in MLR medium at 2x10
6 
cells/mL, and irradiated at 30-35 Gray.  
Plating of cells: One million CFSE-labeled pre-transplant responder cells and one million violet 
dye-labeled irradiated stimulators were plated in each well of a 24-well plate (total well volume 
1mL). For HC#2, HC#3, IS#1, IS#2, and the anti-third party MLRs, we used 96-well plates with 
each well containing 200,000 responder PBMC and 200,000 stimulators (total well volume 
200uL).  MLR cultures were incubated at 37C for 5-6 days.    
Flow Cytometry  
MLR wells were harvested after 6 days of culture. Cells were resuspended in FACS buffer, 
stained for 30 minutes with fluorochome-conjugated antibodies against CD3 (BD Pharmingen
TM
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clone SP34-2, catalog # 552852), CD4 (Biolegend
R 
clone OKT4, catalog # 317426), and CD8 
(BD Pharmingen
TM
 clone DK1, catalog # 557834), washed and filtered before FACS sorting on a 
BD Influx
TM 
cell sorter to isolate two discrete cell populations (violet
-
CD3
+
CD4
+
CFSE
lo 
and 
violet
-
CD3
+
CD8
+
CFSE
lo
) representing the CD4
+ 
and CD8
+
 recipient-derived donor-reactive T 
cells. For unstimulated cell populations, PBMC were thawed and stained with anti-CD3, CD4, 
and CD8, then FACS sorted into CD3
+
CD4
+
 and CD3
+
CD8
+
 populations.   
DNA isolation and sequencing:  Genomic DNA was isolated from sorted cell populations using 
the Qiagen DNeasy Blood and Tissue Kit. DNA was frozen at -20C and shipped on dry ice to 
Adaptive Biotechnologies  for high-throughput TCRB CDR3 sequencing.  The TCR sequencing 
data were retrieved from Adaptive’s ImmunoSeq software. 
In Vitro Immunologic Assays  
Standard MLR, CML, and LDA assays were performed using the methods detailed previously 
(5, 40). 
Computational and Statistical Analysis  
Mapping of the reads, identification of CDR3 regions and V/J genes, and bias adjustment were 
performed by Adaptive(41) through their proprietary software. We receive tabulated TRB 
sequencing data from Adaptive, including CDR3 nucleotide and amino acid sequences, raw copy 
number (read counts), adjusted copy number and frequency, V/J genes and gene families, 
inferred insertions and deletions in V-D-J junctions etc.  
Repertoire diversity: We measured the diversity of each repertoire by two approaches: (a) 
entropy (42) (           , where    is the frequency of clone  ) and clonality (    
         ), where      is the entropy of a repertoire with the same number of clones, each 
having exactly the same frequency; (b) Simpson’s Index (     
 , where pi is the frequency of 
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clone i). Compared to entropy (and clonality), Simpson's index is more sensitive to changes in 
frequency of dominant clones.   
Comparison of repertoires: We measured the difference between two repertoires using Jensen-
Shannon divergence(43) and Pearson correlation, both of which ranges from 0 to 1. We defined 
expanded clones in MLR by a minimum frequency in stimulated samples (f; f is set at 0.01%) 
and fold change (C = frequency in stimulated pre-transplant samples/frequency in unstimulated 
pre-transplant samples; C is conventionally set at 5). We define a clone as detectable if the 
frequency is larger than a threshold (m; m is usually 0.001% for samples with ≥106 T cells 
sequenced with 2 million reads). This threshold was set based on power estimation. We model 
the TCR sequencing procedure by two random processes: the first (P1) is a sample of T cells 
randomly taken from the entire repertoire; the second (P2) is multiplexed PCR cloning of CDR3 
regions from the cells in a sample. Assuming the total number of cells from P1 is  , the total 
number of sequence reads is   (usually     ), and the “quantum efficiency” in P2 (defined as 
the average chance of a cell being cloned in PCR) is  , then the expected total number of cells 
cloned in P2 is   , and the number of reads per cell follows a Poisson distribution with    
 
  
. 
If   is in the order of 40%, then the   is usually larger than 5, which means about 95% of 
sampled cells will be represented by at least two reads, a detection threshold in Adaptive’s 
analytical pipeline. For a clone with a frequency   in the entire repertoire, the number of such 
cells in P2 follows a Poisson distribution with        . Any clone with λ’ > 4 will have a 90% 
of chance of detection. If   is 1 million and   is 40%, then to achieve 85% detection power 
requires   greater than 0.001%.   
Testing expansion and deletion. To test expansion or deletion of clones, we first identified donor-
reactive unique clones (defined as above) in pre-transplant MLR, counted their number (N), and 
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tested if these clones are equally likely to be detectable in unstimulated pre- and post-transplant 
samples. Specifically, we generated a 2x2 contingency table: [                      
     ], where      is the number of detectable pre-identified donor- (or third party-) reactive 
clones in unstimulated pre-transplant and       is the number of detectable clones in 
unstimulated post-transplant samples. Two-sided Fisher’s exact test was performed and p-values 
and odds ratios reported. 
Repertoire turnover analysis. To test whether post-transplant reductions in donor-reactive clones 
were distinguishable from general repertoire turnover, we set the null hypothesis to be that a 
donor-reactive clone is equally likely to be present as any other pre-transplant (pre-tx) clones in 
the post-transplant (post-tx) samples. We defined donor reactive clones as described above, and 
set the threshold of detectability at 10
-6
 (there is no need to adjust for detection power, because 
the comparison is internally controlled within each post-tx sample). For each post-tx sample, we 
generated a 2x2 contigency table: [            ], where    is the number of detected pre-tx 
clones,    is the number of undetected pre-tx clones,    is the number of detected donor-
reactive clones and    is the number of undetected donor-reactive clones. We performed 
Fisher’s exact test to assess significance, and report odds ratio as relative change. 
 
Supplementary Materials 
Fig. S1. Validation study design and analysis details of the tracking of alloreactive clones in 
healthy controls. 
Fig. S2. Anti-donor clonal analysis at increasing fold-expansion criteria. 
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Fig. S3. Frequencies of donor-reactive clones pre- and post-transplant in CKBMT recipients 
(CD4). 
Fig. S4. Frequencies of donor-reactive clones pre- and post-transplant in CKBMT recipients 
(CD8). 
Fig. S5. Limiting dilution analysis (CTLp and HLT) for Subjects 1, 2, 4, and 5. 
Fig. S6. Comparison of pre- and post- transplant anti-donor MLR in Subject 4.  
Fig. S7. Frequencies of donor-reactive clones pre- and post-transplant in the “conventional” 
kidney transplant recipients. 
Fig. S8. Detection of third party-reactive TCR pre- and post-transplant. 
Table S1. Cell counts, entropy, and clonality for healthy control experiments.  
Table S2. Sum frequency of alloreactive clones in healthy controls (%). 
Table S3: Cell numbers, number of unique clones, and total number of reads for each patient 
sample. 
Table S4: Tabulated data from clonal analysis in Subject 1, 2, 4, 5, IS#1, and IS#2 (Figs. 3B, 4).  
Table S5: Tabulated data from clonal analysis in healthy controls (Fig. 4B). 
Table S6: Sum frequency of alloreactive clones in Subject 4 (%). 
Table S7: Relative turnover analysis in tolerant subjects (Fig. 5B). 
Table S8: Cell numbers, number of unique clones, and total number of reads for anti-third-party 
responses. 
Table S9: Relative turnover analysis at increasing fold-expansion criteria: Subject 1 (Fig. 5C).  
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Figures:  
Fig. 1. Mixed lymphocyte reaction experimental design and schematic of TCR sequencing 
analysis strategy to identify and track donor-reactive T cells. A. CD3+Violet- cells, 
representing the responder T cells, were selected and further separated into CD4+ and CD8+ 
subgroups. Within each subgroup, the CFSE-low cells were isolated for DNA extraction and 
TCRβ CDR3 deep sequencing. Sorting strategy is indicated with boxes on the dot plots and bars 
on the histograms; CFSE staining in unstimulated control sample shown in Fig. S1A. B. Pre-
transplant “fingerprint” of anti-donor T cell repertoire defined as all clones detected at a 
frequency greater than 10^-4 in the stimulated condition (CFSE-low cells in MLR) that have 
expanded at least 5-fold relative to their frequency in the unstimulated T cell population 
(unstimulated repertoire defined via TCR sequencing of CD3+CD4+ or CD3+CD8+ T cells 
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isolated via FACS sorting of PBMCs from the same sample used for the CFSE-MLR). Each 
donor-reactive clone identified by its unique CDR3 nucleotide sequence could then be tracked in 
post-transplant unstimulated peripheral blood samples.    
 
Fig. 2. Overlap of the alloreactive T cell repertoire via TCR sequencing in repeat MLR 
assays in healthy controls. A. Top panel: linear correlation of log frequencies of alloreactive 
clones detected in MLRs performed at time point 1 [stimulated (T1)] and time point 2 
[stimulated (T2)] for Healthy Control (HC) #1 from blood draws separated by a two-week 
interval. Second panel from top: no such correlation is observed when clonal frequencies in the 
stimulated populations are plotted against frequencies in the unstimulated population 
[unstimulated (T1)]; high frequency clones in the unstimulated populations highlighted in 
yellow. These results are representative of similar analyses in HC#2 and HC#3 (Fig. S1D). 
Bottom two panels: linear correlation persists in MLRs performed from blood draws separated 
by a year interval (HC#2, HC#3). Same allogeneic stimulator for each HC at T1 and T2. 
Overlapping number of sequences detected: HC#1 T1 & T2 stim CD4 = 2944, CD8 = 465; HC#1 
T1 stim & T1 unstim: CD4 = 3011, CD8 = 478; HC#2 T1 & T2 stim: CD4 =1162, CD8 = 642. 
HC#3 T1 & T2 stim: CD4 =2850, CD8 = 652.  B. Pie charts showing relative overlap of the 
summed frequencies of alloreactive clones (“fingerprint” as defined in Figure 1) over time in 
three healthy controls. Each circle represents the cumulative frequency of all alloreactive clones 
identified in the sample; red segment shows the percentage of that total frequency arising from 
alloreactive clones identified at both T1 and T2 (tabulated values Table S2). C. Boxplot 
comparing the clonality of the unstimulated CD4 and CD8 T cell repertoires (* P = 0.0062, n = 
5, two-tailed paired t test; tabulated values Table S1).  D. Cumulative frequencies of all 
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alloreactive clones for each pair of stimulated and unstimulated HC at all time points.  Stim = 
stimulated; unstim = unstimulated; HC = healthy control.  
 
Figure 3. Clinical course, tracking of donor-reactive T cell clones, MLR, and CML results 
in CKBMT subjects. A. Overview of clinical course. B. Number of donor-reactive TRB CDR3 
clones (y-axis) detected in the unstimulated CD4 (black) and CD8 (white) repertoire at the 
indicated time points (x-axis).  The “fingerprint” of the anti-donor T cell repertoire was defined 
for each subject as clones in the pre-transplant MLR with ≥10-4 frequency that were expanded at 
least 5-fold relative to their frequency in the pre-transplant unstimulated sample (total number 
indicated above the relevant panel). Sufficient power was obtained to consider a frequency of 10
-
5 
as detectable in all unstimulated populations for Subjects 1, 2, 4, and 5x10
-5 
for Subject 5. * P < 
0.05 compared to pre-transplant (P-values Table S4; two-sided Fisher’s exact test). C. MLR:  
proliferative responses to recipient (anti-self), donor (anti-donor) and third party (anti-3
rd
 party) 
relative to proliferation of unstimulated PBMCs are shown at the indicated time points. Each bar 
represents the mean ±SD stimulation index of triplicate cultures. D. CML: responses at the 
indicated time points are shown. MLR and CML data have been previously summarized in 
Kawai et al.(8).  
Figure 4. Tracking of donor-reactive T cell clones in “conventional” kidney transplant 
recipients and summary of clonal analysis results for all six subjects. A. Clinical course and 
number of donor-reactive TRB CDR3 clones (y-axis) detected in the unstimulated CD4 (black) 
and CD8 (white) repertoire at the indicated time points (x-axis). Sufficient power was obtained 
to consider a frequency of 10
-5 
as detectable in all unstimulated populations for IS#1 and 5x10
-5 
for IS#2. * P < 0.05 compared to pre-transplant (P-values Table S4; two-sided Fisher’s exact 
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test). B. Change over time in detection of unstimulated T cell populations of donor-reactive CD4 
and CD8 clones (defined in Fig. 3B legend).  Fold change is the odds ratio of the number of 
donor-reactive clones detected in unstimulated post-transplant CD4 and CD8 populations relative 
to the number detected in unstimulated pre-transplant populations (pre-transplant = 1). Open 
symbol = statistically significant reduction or increase (P-value < 0.05). Tabulated results in 
Tables S4 and S5.  
 
Figure 5. TCR repertoire turnover in kidney allograft recipients.  A. Jensen-Shannon 
Divergence (JSD) comparing pre- and post-transplantation (last post-transplantation time point) 
TCR repertoires. JSD on top 1000 nucleotide clones ranked by frequency (0 denotes identical 
repertoires; 1 denotes complete repertoire divergence). Healthy controls: average JSD on top 
1000 nucleotide clones of two healthy controls in whom TCR sequencing was performed at two 
time points 1 year apart. B. Anti-donor CD4 and CD8 clonal analysis relative to overall 
repertoire turnover. Relative numbers of donor-reactive (as defined in Fig. 3B legend) vs non-
donor-reactive clones (all other clones detected in unstimulated pre-transplant sample) detected 
at any level (threshold detection of assay 10
-6
) in post-transplant samples. Relative change is the 
odds ratio of the relative (post/pre) number of donor-reactive clones divided by the relative 
(post/pre) number of non-donor-reactive clones in unstimulated samples at the same time. A 
value of “1” indicates that the proportion of donor-reactive clones (defined pre-transplant as 
above) detected at a given timepoint was equal to that of all clones (detected pre-transplant) 
detected at the same timepoint. A value <1 indicates lower rate of detection of donor-reactive vs 
all clones and a value >1 indicates greater rate of detection of donor-reactive vs all clones. Open 
symbols = statistically significant reduction or increase (P-value < 0.05; two-sided Fisher’s exact 
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test); tabulated data and P-values in Table S7. C. Anti-donor CD4 and CD8 clonal analysis 
relative to overall repertoire turnover in Subject 1: effect of varying definition of donor reactivity 
by different fold-expansion criteria (frequency in pre-transplant anti-donor MLR/frequency in 
unstimulated pre-transplant sample >5, 7, or 10). Red points are statistically significant (p < 
0.05); tabulated data and P-values in Table S9. 
 
Figure 6. CD4 T cell repertoire diversity (measured by Simpson’s Index D) over time post-
transplantation (D of “1” indicates that all clones are identical, smaller D indicates clones are 
more unique and therefore the repertoire is more diverse). B. Comparison of CD4 Simpson’s 
Index (D) in tolerant (Subjects 1, 2, 4) and non-tolerant (Subject 5, IS#1, and IS2) subjects near 
one year post-transplant (10 months: IS#2; 12 months: Subjects, 2, 4, IS#1; 14 months: Subject 
5; 18 months Subject 1). * P = 0.017; N = 6; two-sided Student's t-test on logarithm of D.) 
 
